Fig. 2: Effect of JNJ-61393215 (3, 10, and 30 mg/kg, oral administration) and its less active enantiomer JNJ-63821238 (30 mg/kg, oral administration) on CO2-induced panic responses. | Translational Psychiatry

Fig. 2: Effect of JNJ-61393215 (3, 10, and 30 mg/kg, oral administration) and its less active enantiomer JNJ-63821238 (30 mg/kg, oral administration) on CO2-induced panic responses.

From: Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans

Fig. 2

Line and bar graphs in all panels represent (A) social interaction time (min), (B) mean arterial blood pressure (mm Hg), C heart rate (beats per min), D general locomotor activity (counts/min), and E core body temperature (celsius) of rats pretreated with 30 mg/kg of JNJ-63821238, the less active enantiomer of JNJ-61393215 (control group, n = 11), or JNJ-61393215 compound at 3 doses (3, 10, and 30 mg/kg with n = 10/group, one rat was discontinued during crossover due to technical complications) p.o. 30 min prior to onset of 10 min of atmospheric air infusions, followed by a 5-min 20% CO2 (normoxic) air infusion (gray shaded region), then another 5-min infusion of atmospheric air. Physiology was obtained from radiotelemetry probes with a pressure transducer in the femoral artery for cardiovascular measures and an internal thermistor for core body temperature. *P < 0.05 and see “Results” for detailed statistical analysis.

Back to article page